- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- May 2024
- 129 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- September 2022
- 177 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- August 2022
Global
From €941EUR$990USD£791GBP
- Report
- January 2024
- 215 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- September 2022
- 113 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- July 2022
- 78 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Drug Pipelines
- October 2020
- 90 Pages
Global
From €1901EUR$2,000USD£1,597GBP
Leishmaniasis is a parasitic disease caused by the Leishmania parasite, which is spread by the bite of certain types of sandflies. Treatment of leishmaniasis is typically done with antimonial drugs, such as pentavalent antimonials, amphotericin B, and miltefosine. These drugs are used to treat both cutaneous and visceral forms of the disease.
The leishmaniasis drug market is a subset of the infectious diseases drug market, which is estimated to be worth billions of dollars. The leishmaniasis drug market is expected to grow due to the increasing prevalence of the disease, especially in tropical and subtropical regions. Additionally, the development of new drugs and treatments for leishmaniasis is expected to drive the market.
Some of the major companies in the leishmaniasis drug market include GlaxoSmithKline, Novartis, Merck, Sanofi, and Pfizer. Additionally, there are several smaller companies that are developing new drugs and treatments for leishmaniasis. Show Less Read more